Biosimilars—why terminology matters
Authors:
- Martina WeiseMWMartina Weise
- Marie-Christine BielskyMBMarie-Christine Bielsky
- Karen De SmetKSKaren De Smet
- Falk EhmannFEFalk Ehmann
- Niklas EkmanNENiklas Ekman
- Gopalan NarayananGNGopalan Narayanan
- Hans-Karl HeimHHHans-Karl Heim
- Esa HeinonenEHEsa Heinonen
- Kowid HoKHKowid Ho
- Robin ThorpeRTRobin Thorpe
- Camille VleminckxCVCamille Vleminckx
- Meenu WadhwaMWMeenu Wadhwa
- 1 August 2011
- journal article
- Published by Springer Nature in Nature Biotechnology
- Vol. 29 (8) , 690-693
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Biosimilar low molecular weight heparin productsJournal of Thrombosis and Haemostasis, 2009
- Impact of illegal trade on the quality of epoetin alfa in ThailandClinical Therapeutics, 2009
- Biosimilar therapeutics--what do we need to consider?NDT Plus, 2009
- Pure red cell aplasia due to follow-on epoetinKidney International, 2008
- Biosimilars: Illustration of scientific issues in two examplesAmerican Journal of Health-System Pharmacy, 2008
- Biosimilar Epoetins: An Analysis Based on Recently Implemented European Medicines Evaluation Agency Guidelines on Comparability of Biopharmaceutical ProteinsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2005
- Characterizing biological products and assessing comparability following manufacturing changesNature Biotechnology, 2004
- Among the contributorsWasafiri, 2003
- FDA notifications. FDA uncovers counterfeit Procrit.2003
- Avaliação da atividade e caracterização de eritropoietina humana recombinante em produtos farmacêuticosArchives of Endocrinology and Metabolism, 2003